• Explore /
  • Poster
  • / Efficacy of the PARP inhibitor (PI) ABT-888 (veliparib [vel]) either with carboplatin (carb) or as a single agent followed by post-progression therapy in combination with carb in patients (pts) with <i>BRCA1</i>- or <i>BRCA2</i>- (<i>BRCA</i>)-associated metastatic breast cancer (MBC).

Efficacy of the PARP inhibitor (PI) ABT-888 (veliparib [vel]) either with carboplatin (carb) or as a single agent followed by post-progression therapy in combination with carb in patients (pts) with BRCA1- or BRCA2- (BRCA)-associated metastatic breast cancer (MBC).

Abstract Poster

Authors

null

George Somlo

City of Hope, Duarte, CA

George Somlo , Paul Henry Frankel , Thehang H. Luu , Cynthia X. Ma , Banu Arun , Agustin A. Garcia , Leah Cream , Harold A. Harvey , Joseph A. Sparano , Rita Nanda , Helen K. Chew , Timothy Jerome Moynihan , Linda T. Vahdat , Matthew P. Goetz , Arti Hurria , Joanne E. Mortimer , David R. Gandara , Alice P. Chen , Jeffrey N. Weitzel , Tessa Cigler

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Breast Cancer—HER2/ER

Track

Breast Cancer

Sub Track

ER+

Clinical Trial Registration Number

NCT01149083

Citation

J Clin Oncol 33, 2015 (suppl; abstr 520)

DOI

10.1200/jco.2015.33.15_suppl.520

Abstract #

520

Poster Bd #

8

Abstract Disclosures

Similar Posters

First Author: George Somlo

First Author: George Somlo

First Author: Ruben Raychaudhuri

First Author: Anne Patsouris